“So, we'll be able to bring this totality of data together to determine whether the recommendations will change, but also what the vaccination schedule will be. So that's to come in 2024.”

In context

“story. But of course, this makes our gene therapy, in a way, the main game to us. Albert Bourla: Then there was a question, Angela, on the RSV. Angela Hwang: Well, as you heard, during the HCIP discussions, our recommendation for ABRYSVO today is really one around shared clinical decision making. But we also were – we were asked to bring additional data when they are ready. And so, just to confirm that we will have additional data in vaccine effectiveness in broader populations, we will have safety data also in broader populations, we will also have immunogenicity data in younger populations. All of this will be, I think, available in the next year when we plan to bring this back to the CDC. In addition to that, actually omitted to mention that we'll also have second season efficacy data. So, we'll be able to bring this totality of data together to determine whether the recommendations will change, but also what the vaccination schedule will be. So that's to come in 2024. Operator: Next, we have Steve Scala with TD Cowen. Steve Scala: As was just noted a couple of minutes ago, the danu data has reached its primary completion. It was a while ago. Albert, when you were asked, you stressed the words totality of the data, implying that you could have seen some part of the data. Mikael, when you were asked, you talked about different indications. These are not confidence building statements. So, I'm curious, what have you seen? And, Mikael, you've said in the past, you were absolutely encouraged and confident in the profile of danu? Are you still absolutely encouraged and confident? So that's the first question. Secondly, a competitor spoke to potentially COVID derived decrease in diagnosis of inflammatory diseases, such as UC, and I'm wondering if you've see”